View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 22, 2019updated 25 Feb 2019 6:07am

PPD and China’s HLT to offer data science-driven clinical trial solutions

US-based contract research organisation Pharmaceutical Product Development (PPD) has partnered with Chinese medical artificial intelligence (AI) provider Happy Life Tech (HLT) to develop data science-driven clinical trial solutions for drug developers.

As part of an exclusive agreement, the companies will also work to offer solutions for real-world evidence of drug products’ effectiveness, safety and value.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The new solutions will combine PPD’s expertise in clinical trial management and evidence generation with HLT’s AI and data technology.

PPD and HLT aim to provide global pharmaceutical companies with improved access to drug development and post-marketing ecosystem in China.

The enhanced access is expected to enable addressing of unmet clinical needs in the country, as well as boost research capabilities for Chinese pharmaceutical industry in the global market.

In specific, the alliance focuses on data-driven feasibility, patient recruitment and real-world evidence offerings for global as well as domestic pharmaceutical and biotech companies.

PPD chairman and CEO David Simmons said: “Our focus on sites with access to eligible patients is designed to speed patient recruitment at high-performing sites and to more effectively incorporate Chinese patients into global trials.

“We will help clients adapt study protocols to the China market, while helping sites enhance quality, drive performance and lead global multicentre trials. In addition, we will intelligently leverage real-world data in China to recruit patients with a high potential for participation in our clients’ studies and to generate real-world insights needed for market access and product uptake.”

HLT found Rujing Gong added that the new solutions will bolster trial efficiency and mitigate costs.

The partners will provide clinical research services such as clinical study protocol design, site selection, patient recruitment and real-world evidence in China.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena